Intetumumab

Cat. No.: HY-P99296

CAS No.: 725735-28-4

Target: EGFR

Pathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Intetumumab (CNTO 95) is a potent anti-EGFR monoclonal antibody that is glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC). Intetumumab can be used in research of cancer[1][2].

In Vitro

Intetumumab (CNTO 95; 0-5 μg/mL; 20 min; USPC-ARK-3 cells) inhibits integrin-mediated USPC cell adherence to a vitronectin substratum and inhibits serum-induced migration of USPC cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Intetumumab (CNTO 95; 10 mg/kg; i.p.; Male nude rats) inhibits tumor growth and inhibits spontaneous lung metastasis of A549 tumors and decreases both the number of rats with lung metastasis and the number of metastatic lesions per lung[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male nude rats with lung metastasis models (5-6 weeks old and 150-200 g)[2]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; once a week for 60 days
Result:	Had the total tumor response rates (CR and PR) was 33% in A549 tumor model. Developed lung metastases only 4 of 9 rats.

REFERENCES

[1]. Bellone M, et, al. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. Int J Gynecol Cancer. 2011 Aug;21(6):1084-90.

[2]. Gonzalez-Nicolini V, et, al. Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy. Clin Cancer Res. 2016 May 15;22(10):2453-61.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA